An Effectiveness and Safety Study of Chinese Herbal Medicine for Functional Constipation
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
Functional constipation (FC) is a common complaint in clinical practice, but treatment for this condition in conventional medicine is suboptimal. Complementary and alternative medicines, especially Chinese herbal medicine (CHM) are used frequently by patients, however, there is little research evidence about these commonly used CHM. The purpose of the study is evaluate the efficacy and safety of an ancient CHM formula, MaZiRenWan (MZRW), by comparing with placebo.
| Condition | Intervention | Phase |
|---|---|---|
|
Functional Gastrointestinal Disorders Constipation |
Drug: MaZiRenWan (MZRW) Drug: Placebo |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Chinese Herbal Medicine for Functional Constipation: A Randomized, Double-blind, Placebo Controlled Trial |
- Responder of Complete Spontaneous Bowel Movement (CSBM) [ Time Frame: End of treatment (wk10) ] [ Designated as safety issue: No ]Patients with a mean increase of ≧1 complete spontaneous bowel movement(CSBM)/wk compared with the baseline(wk1-2) will be defined as responders. CSBM referred to the feeling that defecation led to complete passage of stool rather than partial or incomplete evacuation without the use of any laxative or enema within 24 hours.
- Responder of Complete Spontaneous Bowel Movement (CSBM) [ Time Frame: End of follow up (wk18) ] [ Designated as safety issue: No ]
Participants with a mean increase of complete spontaneous bowel movement (CSBM)>=1 movement per week compared with the last 14 days of the run-in period were defined as responders.
CSBM referred to the feeling that defecation led to complete passage of stool rather than partial or incomplete evacuation without the use of any laxative or enema within 24 hours.
- Bowel Movement [ Time Frame: Baseline(Wk1&2), Within treatment(Wk3-10) & Within follow-up(Wk11-18) ] [ Designated as safety issue: No ]
- Complete Spontaneous Bowel Movement (CSBM) [ Time Frame: Baseline(Wk1&2), Within treatment(Wk3-10), Within follow-up(Wk11-18) ] [ Designated as safety issue: No ]
- Changes on Individual Symptom Scores [ Time Frame: Baseline(Wk2), Within treatment(Wk6), End of treatment(Wk10) & End of follow-up(Wk18) ] [ Designated as safety issue: No ]It was a 7-point ordinal scale from 0=not at all to 6=very severe.
- Global Symptoms Improvement [ Time Frame: Wk 6, 10 & wk 18 ] [ Designated as safety issue: No ]Participants were asked to rate their impression of change in constipation by comparing with their baseline (Wk2) at the visits during the treatment (Wk6), end of treatment (Wk10) and end of follow-up (Wk18) with scores from 0 to 6 represented markedly worse or better respectively. The response categories were collapsed to simply "improved" for score 4 to 6, "same" for score 3 or "worse" for score 0 to 2.
- Success of Blinding [ Time Frame: End of follow-up (Wk18) ] [ Designated as safety issue: No ]The success of blinding was evaluated for both investigator and patients as to whether MZRW or placebo had been taken.
- Blood Urea Level [ Time Frame: Pre-treatment (Wk2) & Post-treatment (Wk10) ] [ Designated as safety issue: Yes ]
- Blood Creatinine Level [ Time Frame: Pre-treatment (Wk2) & Post-treatment (Wk10) ] [ Designated as safety issue: Yes ]
- Serum Glutamic Pyruvic Transaminase(SGPT) Level [ Time Frame: Pre-treatment (Wk2) & Post-treatment (Wk10) ] [ Designated as safety issue: Yes ]
- Serum Glutamic Oxaloacetic Transaminase (SGOT) [ Time Frame: Pre-treatment (Wk2) & Post-treatment (Wk10) ] [ Designated as safety issue: Yes ]
| Enrollment: | 120 |
| Study Start Date: | July 2008 |
| Study Completion Date: | December 2009 |
| Primary Completion Date: | November 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: MaZiRenWan (MZRW)
MZRW granule, 7.5g/sachet
|
Drug: MaZiRenWan (MZRW)
MZRW granule dissolved in 150ml hot water (oral), 7.5g/sachet, twice daily
Other Name: Hemp Seed Pill
|
|
Placebo Comparator: Placebo
Placebo granule, 7.5g/sachet
|
Drug: Placebo
Placebo granule dissolved in 150ml hot water (oral), 7.5g/sachet, twice daily
|
Detailed Description:
Constipation is a common gastrointestinal complaint in clinical practice, which affects in estimated 12%-19% of American, 14% of Asian, and up to 27% of the population depending on demographic factor, sampling, and definition. With the unsatisfactory response to current symptomatic treatments, many patients seek help from traditional Chinese medicine (TCM), mostly by taking Chinese herbal medicine (CHM).
According to the TCM theory, constipation can be broadly divided into two types, excessive and deficient, based on the underlying aetiology. The former is characterized by the presence of Heat or pathological accumulation of Qi. Heat causes constipation by drying the Intestines and the stool. Patients present with hard, dry, pellet like stool, red complexion, dry mouth or halitosis, red tongue with a dry yellow coat, and slippery and rapid pulse. Qi stagnation causes constipation by disrupting the normal movement and descent of Stomach and Intestinal Qi. Patients present difficulty in passing stools, feelings of incomplete evacuation, abdominal distension or pain, frequent belching and flatulence, tongue with thin coat and wiry pulse. The latter, deficient constipation, is delineated as the dryness from insufficient fluid lubrication in the form of blood or lack of propulsion power from the deficiency of Qi or Yang. Besides, the treatment approaches vary from syndrome to syndrome.
The formula of MaZiRenWan (MZRW) composed of six Chinese herbs is firstly recorded in a TCM classic, Discussion of Cold-induced Disorders (Shang Han Lun), and it has been commonly used for constipation in excessive pattern throughout Asia since the Han Dynasty (A.D. 200). By combining the actions of these herbs, MZRW can moisten the Intestines, drain heat, promote the movement of Qi and unblock the bowel. Although previous studies show that MZRW has purgative and laxative effects and may be useful for functional constipation (FC), there are significant methodological weaknesses. Furthermore, the dose of CHM intervention being investigated from the first randomized controlled trial (RCT) published in 1983 is always based on the practitioner's experience, TCM literatures, or experts' comments, but not the results from stringent clinical trials, such as dose determination study. Therefore, the evidence produced will be attenuated or even misleading if improper dose is taken.
In the present study, the efficacy and safety of MZRW in optimal dosage were justified by comparing with placebo under strict clinical trial design.
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Meet of Rome III diagnostic criteria of functional constipation
- Meet the diagnosis of Excessive Constipation according to the TCM theory
- Age of 18 to 65 years (inclusive)
- Complete spontaneous bowel movement (CSBM)≦2times/wk
- Severity of constipation≧4pts (7 pts scale from 0 to 6pts) and the overall scoring of constipation-related symptoms≧8pts (6items in 7pts scale) for self symptom assessment in the run-in period
- Normal colonic evaluation (colonoscopy or barium enema) within 5 years
- Normal liver and renal function in blood test within 3 months
Exclusion Criteria:
- Drug-induced constipation
- Secondary causes of constipation (i.e. medical history of diabetes mellitus and thyroid disease)
- Abdominal surgery (i.e. Caesarean operation)
- Severe disease (i.e. cancer and acute present asthma)
- Allergy to CHM (i.e. G6PD deficiency)
- Pregnancy or breast-feeding
- Psychiatric or addictive disorders
Contacts and Locations| China | |
| Hong Kong Baptist University Mr. & Mrs. Chan Hon Yin Chinese Medicine Specialty Clinic and Good Clinical Practice Centre | |
| Hong Kong, China | |
| Principal Investigator: | Zhao-xiang Bian, PhD | Hong Kong Baptist University |
More Information
Additional Information:
Publications:
| Responsible Party: | ZhaoXiang Bian, Professor, Director of Clinical Division, Hong Kong Baptist University |
| ClinicalTrials.gov Identifier: | NCT00741936 History of Changes |
| Other Study ID Numbers: | PID-002 |
| Study First Received: | August 25, 2008 |
| Results First Received: | August 2, 2011 |
| Last Updated: | November 14, 2011 |
| Health Authority: | Hong Kong: Joint CUHK-NTEC Clinical Research Ethics Committee |
Keywords provided by Hong Kong Baptist University:
|
Functional Constipation Chinese Herbal Medicine MaZiRenWan |
Hemp Seed Pill Traditional Chinese Medicine Herbal Medicine |
Additional relevant MeSH terms:
|
Constipation Digestive System Diseases Gastrointestinal Diseases Signs and Symptoms, Digestive Signs and Symptoms |
ClinicalTrials.gov processed this record on May 19, 2013